

WEST**End of Result Set**

Generate Collection

L34: Entry 2 of 2

File: DWPI

Jun 2, 1999

DERWENT-ACC-NO: 1997-424744

DERWENT-WEEK: 199926

COPYRIGHT 2002 DERWENT INFORMATION LTD

TITLE: Use of cholinesterase inhibitors for treating arthritis - especially galantamine or derivative, or prodrug

INVENTOR: MURRAY, J; SNORRASON, E

PATENT-ASSIGNEE:

ASSIGNEE

CODE

SNORRASON E

SNORI

PRIORITY-DATA: 1996GB-0006736 (March 29, 1996), 1996IS-0004325 (February 19, 1996)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
EP 918523 A1	June 2, 1999	E	000	A61K031/55
WO 9729750 A1	August 21, 1997	E	035	A61K031/55
AU 9721059 A	September 2, 1997		000	A61K031/55

DESIGNATED-STATES: AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN YU AT BE CH DE DK EA ES FI FR GB GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
EP 918523A1	February 19, 1997	1997EP-0906339	
EP 918523A1	February 19, 1997	1997WO-IS00001	
EP 918523A1		WO 9729750	Based on
WO 9729750A1	February 19, 1997	1997WO-IS00001	
AU 9721059A	February 19, 1997	1997AU-0021059	
AU 9721059A		WO 9729750	Based on

INT-CL (IPC): A61K 31/55; A61K 45/06

ABSTRACTED-PUB-NO: WO 9729750A

BASIC-ABSTRACT:

The use of a cholinesterase inhibitor (A) or its prodrug is claimed for preparing compositions for the prevention and treatment of arthritic disorders.

Preferably (A) is galantamine, epigalantamine, norgalantamine or derivatives of these, physostigmine, tacrine or its analogues, fasciculins, metrifonate, heptylphysostigmine, norpyridostigmine, norneostigmine or huperzine, or prodrugs of these.

USE - (A), especially galantamine, is used to treat rheumatic disorders, including juvenile arthritis, systemic lupus erythematosus, Sjogren's syndrome, progressive systemic sclerosis, polymyositis, dermatomyositis, ankylosing spondylitis, Reiter's syndrome, psoriatic arthritis, relapsing polychondritis, relapsing panniculitis, Crohn's disease, ulcerative colitis,

hereditary complement deficiencies, collagen vascular disease, Felty's syndrome, rheumatological manifestations associated with bacterial and viral endocarditis or myocarditis, anaemia of chronic disorder, and especially rheumatoid arthritis and osteoarthritis (all claimed). Administration is by tablet, capsule, sustained release capsule, solution, suspension, transdermal device, suppository or implant. Dosage of (A) is equipotent with 0.1-1000 mg galantamine hydrobromide per day, parenterally (all claimed). (A) may be given orally, sc. or iv.

ADVANTAGE - Galantamine has a long half life and few side effects.

CHOSEN-DRAWING: Dwg.0/0

TITLE-TERMS: CHOLINESTERASE INHIBIT TREAT ARTHRITIS DERIVATIVE PRODRUG

DERWENT-CLASS: B02

CPI-CODES: B06-E05; B14-C09; B14-D07A;

CHEMICAL-CODES:

Chemical Indexing M2 *01*

Fragmentation Code

B615 B711 B720 B731 B742 B743 B760 B792 B813 B831
 B840 C009 C017 C035 C053 D000 D011 D012 D013 D014
 D015 D019 D021 D022 D023 D024 D025 D026 D029 D030
 D220 E310 E330 E540 F010 F020 G001 G002 G010 G011
 G012 G013 G019 G020 G021 G022 G029 G030 G040 G050
 G100 G111 G112 G113 G221 G299 G553 G563 H100 H101
 H102 H121 H141 H142 H143 H161 H162 H163 H181 H182
 H183 H201 H202 H211 H212 H321 H322 H341 H342 H343
 H361 H362 H381 H382 H383 H401 H402 H403 H404 H405
 H441 H461 H481 H482 H483 H484 H494 H496 H498 H521
 H522 H541 H542 H543 H561 H562 H563 H581 H582 H583
 H594 H596 H599 H601 H602 H603 H604 H608 H609 H621
 H622 H623 H641 H642 H643 H661 H662 H681 H682 H683
 H685 H689 H713 H716 H721 J011 J012 J013 J171 J172
 J231 J232 J241 J242 J261 J331 J332 J341 J351 J561
 J581 J582 J583 J596 K130 K610 K620 K630 K640 K699
 K850 K899 L110 L143 L144 L145 L431 L640 L699 L960
 M111 M112 M113 M114 M115 M119 M121 M122 M123 M124
 M125 M129 M132 M135 M136 M139 M141 M142 M143 M149
 M150 M210 M211 M212 M213 M214 M215 M216 M220 M221
 M222 M223 M224 M225 M226 M231 M232 M233 M240 M250
 M262 M271 M272 M273 M280 M281 M282 M283 M311 M312
 M313 M314 M315 M316 M320 M321 M322 M323 M331 M332
 M333 M334 M340 M342 M343 M344 M349 M351 M353 M361
 M362 M373 M381 M383 M391 M392 M393 M411 M412 M511
 M520 M521 M530 M531 M532 M533 M540 M541 M630 M640
 M650 M781 M903 M904 P210 P220 P411 P421 P423 P528
 P616 P732 P738 P811 P812 P943 V813

Ring Index

13240

Markush Compounds

199739-24601-U

Chemical Indexing M2 *02*

Fragmentation Code

D011 D019 D022 D030 E250 H1 H182 H2 H202 K0
 L4 L463 M210 M211 M240 M273 M281 M283 M320 M412
 M511 M520 M530 M540 M781 M903 M904 M910 P210 P220
 P411 P421 P423 P528 P616 P732 P738 P811 P812 P943
 V813

Ring Index

02442

Specific Compounds

00133U

Registry Numbers

0133U

Chemical Indexing M2 *03*

Record Display Form

Fragmentation Code

D011 E112 H1 H100 H121 M280 M320 M412 M511 M520
M530 M540 M781 M903 M904 P210 P220 P411 P421 P423
P528 P616 P732 P738 P811 P812 P943 V813

Specific Compounds

17015U

Chemical Indexing M2 *04*

Fragmentation Code

B415 B701 B712 B720 B741 B815 B831 H4 H401 H481
H6 H602 H609 H686 H8 M210 M211 M272 M282 M312
M321 M332 M344 M361 M391 M411 M510 M520 M530 M540
M620 M781 M903 M904 M910 P210 P220 P411 P421 P423
P528 P616 P732 P738 P811 P812 P943 V813

Specific Compounds

00065U

Registry Numbers

0065U

UNLINKED-DERWENT-REGISTRY-NUMBERS: 0065U; 0133U

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1997-135880